Forest and Merz settle Namenda litigation

Published: 27-Jul-2010
Finance

Generic versions of drug to enter market in 2015


Pharmaceutical developer Forest Laboratories of the US and partner Merz Pharmaceuticals of Germany have signed a patent litigation settlement agreement with 10 firms that were seeking to launch generic versions of Alzheimer’s drug Namenda (memantine hydrochloride) immediate release tablets.

Under the settlement agreements, the first generic versions of memantine will enter the market on 11 January 2015. This settlement agreement is subject to review by the US Federal Trade Commission.

Forest and Merz will provide licenses to Amneal, Watson, Dr. Reddy’s, Lupin, Mylan, Orchid, Sun, Teva, Upsher-Smith, and Wockhardt.

  • Companies:
  • Forest Laboratories Inc
  • Dr Reddys Laboratories
  • Wockhardt Group
  • Merz
See more

You may also like

Finance

Acino and Merz Therapeutics sign Ukraine distribution agreement

Read more
Under the agreement, Acino will commercialise the product portfolio of Merz Therapeutics in the areas of gastroenterology, neurology and dermatology

Trending Articles

  1. Piramal Pharma Limited reports robust growth in CDMO and sustainability initiatives US$80 million Lexington expansion to double sterile fill-finish capacity
  2. GSK bolsters its US drug manufacturing capabilities with $800m investment The expansion will double the size and capacity of its Marietta site, supporting the manufacture of sterile liquid vaccines and production for clinical trials
  3. Lupin acquires Biocom in Russia Acquisition marks Lupin's foray into the Russian pharma market, which recorded RUB765bn in sales in 2014
  4. Axol Bioscience boosts its iPSC bioassay offering with Phenocell acquisition The acquisition will extend Axol's range of iPSC-derived cell lines, including skin and retinal cells — while also expanding its drug discovery services
  5. Eli Lilly to leverage ViaNautis Bio's nanovesicle technology for genetic medicine development ViaNautis' polyNaut nanovesicles can deliver genetic materials to specific tissues or cell types, allowing for more accurate therapeutic targeting

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Finance

Acino and Merz Therapeutics sign Ukraine distribution agreement

Under the agreement, Acino will commercialise the product portfolio of Merz Therapeutics in the areas of gastroenterology, neurology and dermatology
Manufacturing

Dr. Reddy’s and TR-Pharm announce strategic collaboration in Turkey

Dr. Reddy’s and TR-Pharm have entered into a strategic collaboration agreement to manufacture and commercialise a portfolio of biosimilar drugs in Turkey
Research & Development

Dr Reddy’s raises its R&D spending

Biosimilars account for around 15–20% of the overall R&D spend, representing US$45–60m
Finance

Dr Reddy’s to buy allergies and respiratory franchises in India from UCB for €118m

Strengthens its presence in dermatology, respiratory and paediatrics medicines
Finance

Operating margins expected to grow by 28% year-on-year for Indian pharma firms

Most are focusing on niche products in the US
Finance

Actavis completes US$28bn purchase of Forest Laboratories

Names new management team
Finance

Actavis to acquire Forest Laboratories for US$25bn

Creates a company with US$15bn in revenue and a growing $7bn North American speciality brand business
Subscribe now